The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome (STADIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00990197
Recruitment Status : Suspended (Difficulties with enrollment.)
First Posted : October 6, 2009
Last Update Posted : October 6, 2009
Canadian Tobacco Control Research Initiative
Information provided by:
Sir Mortimer B. Davis - Jewish General Hospital

No Study Results Posted on for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : July 2009
  Estimated Study Completion Date : December 2009
Cardiovascular Disease Surveillance. Laboratory Centre for Disease Control, Statistics Canada 2002, Candian Institutes for Health Information (CIHI), 2002.
Hwang SL WM. Heart attacks reported in patch users still smoking. Wall Street Journal 1992;(June 19):B1.
Treating tobacco dependence: a report of the Surgeon General. Washington, DC: Department of Health and Human Services, 2000.
Freedman D PRPR. Statistics. New York: Norton Publishers, 1978.
Hughes JR, Glaser M. Transdermal nicotine for smoking cessation. Health Values 1993; 17(2):25-31.
American Medical Association. Drug Evaluations Annual 1994. Chicago: American Medical Association 1993.
Moyer D. Chapter 13: Physical fitness and carbon monoxide. Tobacco Reference Guide 2000;30-34.